$ cat ./records/gates-foundation-secures-50-price-cut-on-jadelle-contraceptive-im-2013.txt
Gates Foundation Secures 50% Price Cut on Jadelle Contraceptive Implant Globally
[RECORD.TXT] · cat --full
The Gates Foundation negotiated a landmark price-guarantee agreement with Bayer and Merck that reduced the cost of the Jadelle levonorgestrel implant from $18 to $8.50 per unit — a 53 percent reduction — effective January 2013, available in more than 50 countries. A parallel agreement with Merck for its Implanon NXT implant generated $120 million in additional savings. Together the two agreements produced nearly $500 million in cumulative procurement savings over the guarantee term, enabling governments and NGOs to distribute millions more long-acting reversible contraceptives to women in sub-Saharan Africa who could not previously afford them.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Invests in Beyond Meat — Plant-Based Meat Reducing Land and Water Use
Next →
Melinda Gates Meets Epstein Once and Finds the Encounter Deeply Disturbing
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.